Zhuhai Trinomab Pharmaceutical (SHA:688806) obtained approval from China's National Medical Products Administration to market the retavibart injection, according to a Shanghai bourse filing on Friday.
The drug is used as a prevention of lower respiratory tract infections caused by respiratory syncytial virus in neonates and infants.